Literature DB >> 1374298

Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery.

A W Clowes1, M M Clowes, T R Kirkman, C L Jackson, Y P Au, R Kenagy.   

Abstract

Smooth muscle cells (SMCs) in balloon-injured rat carotid artery express tissue-type plasminogen activator (t-PA) at a time when they are migrating from the media to the intima. Since heparin inhibits SMC migration and intimal thickening, we have examined the possibility that heparin might also inhibit t-PA expression. Heparin (nonanticoagulant fraction; molecular weight, approximately 6,000) was administered by continuous intravenous infusion (1.0 mg/kg per hour) to Sprague-Dawley rats subjected to balloon injury of the left common carotid artery. At various times up to 14 days after injury, plasminogen activator expression was analyzed by zymography, plasmin generation, enzyme-linked immunosorbent assay, Northern blotting, and in situ hybridization. This dose of heparin inhibited SMC accumulation at 14 days by 60%. Both urokinase plasminogen activator (u-PA) and t-PA activity increased in injured arteries and reached a maximum at 7 days. Heparin treatment decreased t-PA, but not u-PA, activity. Total t-PA protein was decreased by treatment with heparin but not chondroitin sulfate, and the decrease in t-PA protein was associated with decreased t-PA mRNA in the media. These results in the injured rat carotid artery agree with our earlier observations that heparin inhibits t-PA gene expression in cultured baboon aortic SMCs. They also provide support for the hypothesis that heparin interferes with the expression of certain proteases required for SMC migration and proliferation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374298     DOI: 10.1161/01.res.70.6.1128

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.

Authors:  V Stepanova; S Mukhina; E Köhler; T J Resink; P Erne; V A Tkachuk
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

Review 2.  Serum-derived growth factor is thrombin?

Authors:  S M Schwartz
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 3.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1994-06

4.  Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.

Authors:  M K Patel; J S Refson; M Schachter; A D Hughes
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  Impaired arterial neointima formation in mice with disruption of the plasminogen gene.

Authors:  P Carmeliet; L Moons; V Ploplis; E Plow; D Collen
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

6.  Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Phosphorothioate Oligodeoxynucleotide Inhibition of Restenosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

8.  Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells.

Authors:  R D Kenagy; S T Nikkari; H G Welgus; A W Clowes
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Basic fibroblast growth factor: its role in the control of smooth muscle cell migration.

Authors:  C L Jackson; M A Reidy
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

10.  Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.

Authors:  Juan F Santibanez
Journal:  ISRN Dermatol       Date:  2013-07-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.